trending Market Intelligence /marketintelligence/en/news-insights/trending/X7Do18B95_GC8wR8bTwTXg2 content esgSubNav
In This List

Cochlear gets US FDA approval for Osia 2 ear implant

Blog

Insight Weekly: Energy crisis cripples Europe; i-bank incomes rise; US holiday sales outlook

Blog

Japan M&A By the Numbers: Q3 2022

Blog

Insight Weekly: Reviving nuclear power; 2023 outlook for US financials; PE funds fuel EV sector

Blog

Insight Weekly: Energy reforms after midterms; Crisis ends 'age of gas'; bank deposits fall


Cochlear gets US FDA approval for Osia 2 ear implant

Australia's Cochlear Ltd. said the U.S. Food and Drug Administration approved its Osia 2 System, an implantable hearing solution that uses wireless technology.

The healthcare equipment company expects to make the device commercially available for patients in the U.S. in early 2020.

The FDA also approved Cochlear's Nucleus Profile Plus series ear implant in June. The agency classifies cochlear implants as Class III devices, which go through the highest level of regulatory scrutiny.